Evidence map›Paper›PMID 34356529›Full record

ArticleBiology2021

Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma.

Pei-Jhang Chiang, Ting Xu, Tai-Lung Cha, Yi-Ta Tsai, Shu-Yu Liu, Sheng-Tang Wu, En Meng, Chih-Wei Tsao, Chien-Chang Kao, Chin-Li Chen and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Predicting response to patients with gastric cancer via a dynamic-aware model with longitudinal liquid biopsy data.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Pei-Jhang ChiangDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.ORCID 0000-0003-2238-5012
Ting XuGraduate School of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan.
Tai-Lung ChaDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Yi-Ta TsaiDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Shu-Yu LiuGraduate School of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan.
Sheng-Tang WuDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
En MengDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Chih-Wei TsaoDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.ORCID 0000-0001-7214-8766
Chien-Chang KaoDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.ORCID 0000-0003-0107-4450
Chin-Li ChenDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Guang-Huan SunDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Dah-Shyong YuDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Sun-Yran ChangDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Ming-Hsin YangDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Tri-Service General Hospital · TWNational Defense Medical Center · TW

Funding

Ministry of National Defense-Medical Affairs Bureau MAB-106-107, MAB-107-082, MAB-107-076, MAB-108-076, MAB-108-075Ministry of Science and Technology MOST 104-2314-B-016-041-MY3, MOST 105-2314-B-016-051-MY3, MOST 105-2314-B-016-012, MOST 106-2314-B-016-029, MOST 107-2314-B-016-039-MY3, MOST 107-2314-B-016-024, MOST 108-2314-B-016-012Tri-Service General Hospital Research Foundation TSGH-C103-058, TSGH-C104-055, TSGH-C105-054, TSGH-C105-006-008-S01, TSGH-C106-004-006-008-S01, TSGH-C106-043, TSGH-C107-008-S01, TSGH-C108-007-008-S01, TSGH-C01-109012, and TSGH-D-109068VGH, TSGH, AS Joint Research Program VTA105-T-2-1, VTA106-T-4-1, VTA107-T-2-1
6 · The paper itself

Abstract

Programmed cell death ligand 1 (PD-L1) inhibitors are commonly used in treating advanced-stage urothelial carcinoma (UC). Therefore, this study evaluated the relationship between PD-L1 expression in circulating tumor cells (CTCs) and treatment response to PD-L1 inhibitors using blood samples collected from patients with UC (

Indexed as

circulating tumor cellsPD-L1PD-L1 inhibitorsurothelial carcinoma

Identifiers

PMID34356529
PMCPMC8301435
OpenAlexW3187029177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.